Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
piracetam + vinpocetine + betahistine
- Development stage
- Unknown
- Lead developer
- Elliott Labs
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Piracetam + Vinpocetine + Betahistine is a fixed-dose combination therapy developed by Elliott Labs for the treatment of vertigo and cognitive symptoms associated with dementia. This combination leverages the synergistic effects of three distinct pharmacological agents: piracetam, a nootropic that acts as a positive allosteric modulator of AMPA-type glutamate receptors to enhance cognitive function and membrane fluidity; vinpocetine, a cerebral vasodilator and neuroprotective agent that inhibits phosphodiesterase 1 (PDE1) and voltage-gated sodium channels to improve cerebral blood flow and neurometabolism; and betahistine, a histamine H3 receptor antagonist and H1 receptor agonist that improves microcirculation in the inner ear and facilitates vestibular compensation. The product is marketed in India as an oral formulation (tablet or capsule) for patients requiring neurometabolic support and vestibular suppression.
- Other names
- Piracetam + Vinpocetine + Betahistine combination
02
Targets
NaV (Voltage-gated sodium channels)HRH1 (Histamine H1 Receptor)AMPAR (AMPA receptor)PDE1 (Phosphodiesterase 1)HRH3 (Histamine Receptor H3)
Beyond the preview
Go deeper on piracetam + vinpocetine + betahistine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on piracetam + vinpocetine + betahistine.